Aardvark Therapeutics, Inc. (AARD) Latest Company News

Oct 23, 2026, 14:47 UTC
The FDA lifted its clinical hold on Aardvark Therapeutics, Inc.’ Phase 3 HERO trial and open-label extension study of ARD-101, allowing clinical development to resume.
Source:
- s.kabutan.jp
Oct 23, 2026, 14:47 UTC
Aardvark Therapeutics, Inc. shares fell 48.61% to $2.03.
Source:
- s.kabutan.jp
- benzinga.com
Oct 12, 2026, 06:29 UTC
A class action lawsuit alleging federal securities law violations was filed against Aardvark Therapeutics, Inc.
Source:
- prnewswire.com
Sep 23, 2026, 21:28 UTC
Kuehn Law, PLLC announced it is investigating whether certain officers and directors of Aardvark Therapeutics, Inc. breached their fiduciary duties to shareholders.
Source:
- prnewswire.com
Sep 10, 2026, 19:57 UTC
Moore Law PLLC announced it is investigating potential claims against the officers and directors of Aardvark Therapeutics, Inc. on behalf of shareholders.
Source:
- prnewswire.com
Aug 20, 2026, 18:32 UTC
A lawsuit was filed against Aardvark Therapeutics, Inc. on behalf of certain investors who purchased shares between February 13, 2025 and May 14, 2026, with a deadline of October 31, 2026 for investors to act.
Source:
Aug 20, 2026, 13:54 UTC
Hagens Berman Sobol Shapiro LLP notified investors of a pending securities class action lawsuit against Aardvark Therapeutics, Inc. related to its IPO and subsequent securities purchases.
Source:
- barchart.com
Aug 14, 2026, 23:47 UTC
A class action lawsuit was filed against Aardvark Therapeutics, Inc. alleging the company misled investors about the viability and efficacy of its lead drug candidate ARD-101, covering purchasers of its IPO stock and securities during the Class Period from February 13, 2025 to May 14, 2026.
Source:
Aug 11, 2026, 20:53 UTC
Aardvark Therapeutics reported its financial results for the second quarter of 2026 and provided business updates.
Source:
- globenewswire.com
Jun 2, 2026, 20:30 UTC
Aardvark Therapeutics stopped its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome, triggering a 56% share price drop and an investigation by Hagens Berman into possible securities law violations.
Source:

AARD

The FDA lifted its clinical hold on Aardvark Therapeutics, Inc.’ Phase 3 HERO trial and open-label extension study of ARD-101, allowing clinical development to resume.

Aardvark Therapeutics, Inc. shares fell 48.61% to $2.03.

A class action lawsuit alleging federal securities law violations was filed against Aardvark Therapeutics, Inc.

Kuehn Law, PLLC announced it is investigating whether certain officers and directors of Aardvark Therapeutics, Inc. breached their fiduciary duties to shareholders.

Moore Law PLLC announced it is investigating potential claims against the officers and directors of Aardvark Therapeutics, Inc. on behalf of shareholders.

A lawsuit was filed against Aardvark Therapeutics, Inc. on behalf of certain investors who purchased shares between February 13, 2025 and May 14, 2026, with a deadline of October 31, 2026 for investors to act.

Hagens Berman Sobol Shapiro LLP notified investors of a pending securities class action lawsuit against Aardvark Therapeutics, Inc. related to its IPO and subsequent securities purchases.

A class action lawsuit was filed against Aardvark Therapeutics, Inc. alleging the company misled investors about the viability and efficacy of its lead drug candidate ARD-101, covering purchasers of its IPO stock and securities during the Class Period from February 13, 2025 to May 14, 2026.

Aardvark Therapeutics reported its financial results for the second quarter of 2026 and provided business updates.

Aardvark Therapeutics stopped its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome, triggering a 56% share price drop and an investigation by Hagens Berman into possible securities law violations.